Epalrestat (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Epalrestat" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

7doi.org

2^nd place

2semanticscholar.org

11^th place

8^th place

1diabetesjournals.org

low place

1harvard.edu

18^th place

17^th place

diabetesjournals.org

care.diabetesjournals.org

Hotta, N; Akanuma, Y; Kawamori, R; Matsuoka, K; Oka, Y; Shichiri, M (July 2006). "Long-Term Clinical Effects of Epalrestat, an". Diabetes Care. 29 (7): 1538–44. doi:10.2337/dc05-2370. PMID 16801576. Retrieved 16 July 2016.

doi.org

Ramirez, Mary Ann; Borja, Nancy L (May 2008). "Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy". Pharmacotherapy. 28 (5): 646–655. doi:10.1592/phco.28.5.646. PMID 18447661. S2CID 207233270.
Steele, John W.; Faulds, Diana; Goa, Karen L. (1993). "Epalrestat". Drugs & Aging. 3 (6): 532–555. doi:10.2165/00002512-199303060-00007. PMID 8312678.
Ramirez, Mary Ann; Borja, Nancy L (May 2008). "Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy". Pharmacotherapy. 28 (5): 646–655. doi:10.1592/phco.28.5.646. PMID 18447661. S2CID 207233270.
Hotta, N; Akanuma, Y; Kawamori, R; Matsuoka, K; Oka, Y; Shichiri, M (July 2006). "Long-Term Clinical Effects of Epalrestat, an". Diabetes Care. 29 (7): 1538–44. doi:10.2337/dc05-2370. PMID 16801576. Retrieved 16 July 2016.
Hotta, N; Sakamoto, N; Shigeta, Y; Kikkawa, G; Goto, Y; Diabetic Neuropathy Study (1996). "Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study". J Diabetes Complications. 10 (3): 168–72. doi:10.1016/1056-8727(96)00113-4. PMID 8807467.
Goto, Y; Hotta, N; Shigeta, Y; Sakamoto, N; Kikkawa, R (1995). "Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study". Biomed Pharmacother. 49 (6): 269–77. doi:10.1016/0753-3322(96)82642-4. PMID 7579007.
Xin, Hu; Li, Shengbing; Yang, Gangyi; Liu, Hua; Boden, Guenther; Li, Ling (2014). "Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis". PLOS ONE. 9 (2): e87096. Bibcode:2014PLoSO...987096H. doi:10.1371/journal.pone.0087096. PMC 3922720. PMID 24533052.

harvard.edu

ui.adsabs.harvard.edu

Xin, Hu; Li, Shengbing; Yang, Gangyi; Liu, Hua; Boden, Guenther; Li, Ling (2014). "Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis". PLOS ONE. 9 (2): e87096. Bibcode:2014PLoSO...987096H. doi:10.1371/journal.pone.0087096. PMC 3922720. PMID 24533052.

nih.gov

pubmed.ncbi.nlm.nih.gov

Terashima, H; Hama, K (1984). "Effects of a new aldose reductase inhibitor on various tissue in vitro". J Pharmacol Exp Ther. 229 (1): 226–230. PMID 6423811.
Ramirez, Mary Ann; Borja, Nancy L (May 2008). "Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy". Pharmacotherapy. 28 (5): 646–655. doi:10.1592/phco.28.5.646. PMID 18447661. S2CID 207233270.
Steele, John W.; Faulds, Diana; Goa, Karen L. (1993). "Epalrestat". Drugs & Aging. 3 (6): 532–555. doi:10.2165/00002512-199303060-00007. PMID 8312678.
Ramirez, Mary Ann; Borja, Nancy L (May 2008). "Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy". Pharmacotherapy. 28 (5): 646–655. doi:10.1592/phco.28.5.646. PMID 18447661. S2CID 207233270.
Hotta, N; Akanuma, Y; Kawamori, R; Matsuoka, K; Oka, Y; Shichiri, M (July 2006). "Long-Term Clinical Effects of Epalrestat, an". Diabetes Care. 29 (7): 1538–44. doi:10.2337/dc05-2370. PMID 16801576. Retrieved 16 July 2016.
Terashima, H; Hama, K; Yamamoto, R; Tsuboshima, M; Kikkawa, R; Hatanaka, I (1984). "Effects of a new aldose reductase inhibitor on various tissues in vitro". J Pharmacol Exp Ther. 229 (1): 226–30. PMID 6423811.
Hotta, N; Sakamoto, N; Shigeta, Y; Kikkawa, G; Goto, Y; Diabetic Neuropathy Study (1996). "Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study". J Diabetes Complications. 10 (3): 168–72. doi:10.1016/1056-8727(96)00113-4. PMID 8807467.
Goto, Y; Hotta, N; Shigeta, Y; Sakamoto, N; Kikkawa, R (1995). "Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study". Biomed Pharmacother. 49 (6): 269–77. doi:10.1016/0753-3322(96)82642-4. PMID 7579007.
Xin, Hu; Li, Shengbing; Yang, Gangyi; Liu, Hua; Boden, Guenther; Li, Ling (2014). "Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis". PLOS ONE. 9 (2): e87096. Bibcode:2014PLoSO...987096H. doi:10.1371/journal.pone.0087096. PMC 3922720. PMID 24533052.

ncbi.nlm.nih.gov

Xin, Hu; Li, Shengbing; Yang, Gangyi; Liu, Hua; Boden, Guenther; Li, Ling (2014). "Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis". PLOS ONE. 9 (2): e87096. Bibcode:2014PLoSO...987096H. doi:10.1371/journal.pone.0087096. PMC 3922720. PMID 24533052.

semanticscholar.org

api.semanticscholar.org

Ramirez, Mary Ann; Borja, Nancy L (May 2008). "Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy". Pharmacotherapy. 28 (5): 646–655. doi:10.1592/phco.28.5.646. PMID 18447661. S2CID 207233270.
Ramirez, Mary Ann; Borja, Nancy L (May 2008). "Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy". Pharmacotherapy. 28 (5): 646–655. doi:10.1592/phco.28.5.646. PMID 18447661. S2CID 207233270.